JP3239660U - oral tablet - Google Patents

Abstract

An object of the present invention is to provide an oral tablet useful for preventing osteoporosis, which is excellent in portability and easy ingestion. [Solution] The oral tablet comprises a solid form tablet body 10 formed by mixing a powdered or granular composite formulation, and a film coating layer 20 covering the outer surface of the tablet body. The formulation contains chicken breast cartilage-derived hydrolyzed granules 11, calcium citrate granules 12, mangosteen extract granules 13, turmeric extract granules 14, and soybean extract granules. 15 and an extract granule 16 derived from nasal cartilage of salmon. [Selection drawing] Fig. 4

Description

The present invention relates to an oral tablet, and more particularly to an oral tablet that is easy to carry and easy to take.

Calcium efflux from bone is an asymptomatic physiological phenomenon that is difficult to notice. As a method for preventing osteoporosis, it is necessary to pay attention mainly to behavior in daily life, such as moderate exercise and eating a well-balanced diet.

However, since it is difficult to ingest various nutrients to maintain bone health from normal meals, how can we develop foods that are excellent in portability and ease of intake to contain various nutrients that are useful in preventing osteoporosis? The biggest issue was how to manufacture it.

The present invention has been made in view of the above problems, and an object of the present invention is to provide an oral tablet useful for osteoporosis prevention which is excellent in portability and ingestion convenience.

In order to achieve the above object, the present invention provides an oral tablet, which is a solid form tablet body composed of a mixture of powdery and granular complex formulations, and a film coating covering the outer surface of the tablet body. a layer, wherein the composite formulation contains hydrolyzed granules derived from chicken breast cartilage, calcium citrate granules, mangosteen extract granules, turmeric extract granules, and soybean extract It is characterized by containing a granular material and an extract powder derived from nasal cartilage of salmon.

As described above, the oral tablet of the present invention contains various nutrients that help prevent osteoporosis, is excellent in portability and ingestion, and has excellent storage stability because the outer surface of the tablet body is coated with a film coating layer. It can be easily taken while improving the

1 is an external perspective view showing a preferred embodiment of the present invention; FIG. 1 is an external side view showing a preferred embodiment of the present invention; FIG. 1 is a cross-sectional view of a preferred embodiment of the present invention; FIG. 1 is a partially enlarged schematic diagram showing a preferred embodiment of the present invention; FIG.

As shown in FIGS. 1-4, the oral tablet of the present invention comprises a tablet body 10 and a film coating layer 20. FIG.

The tablet body 10 is in a solid form obtained by mixing a composite preparation in the form of granules. Hydrolysate Powder 11, Calcium Citrate Powder 12, Mangosteen Extract Powder 13, Turmeric Extract Powder 14, Soybean Extract Contains powder 15 and Salmon Nasal Cartilage Extract powder 16 .

The chicken breast cartilage-derived hydrolyzed granules 11 contain collagen Type II such as chondroitin, hyaluronic acid (HA), and glucosamine, and mucopolysaccharides. The turmeric extract powder 14 contains curcumin, which has anti-inflammatory and antioxidant effects. The salmon nasal cartilage-derived extract granules 16 contain Undenatured Type II Collagen and Undenatured Proteoglycan.

The particle size of the hydrolyzed granules 11 derived from chicken breast cartilage is 180 micrometers (μm) or less, and the particle size of the mangosteen extract granules 13 is 380 micrometers (μm) or less. It is preferable that the grain size of the material 14 is 180 micrometers (μm) or less. When the hydrolyzed granules 11 derived from chicken breast cartilage and the turmeric extract granules 14 are passed through a sieve of 80 meshes, a granule having a particle size of 180 micrometers (μm) or less is obtained, and mangosteen is obtained. When the extract granules 13 are passed through a 40-mesh sieve, granules having a particle size of 380 micrometers (μm) or less are obtained.

The film coating layer 20 covers the outer surface of the tablet body 10 to prevent the tablet body 10 from losing its shape and deterioration, and to improve the storage stability and administration properties of the tablet body 10 . Incidentally, the color of the film coating layer 20 is preferably yellow.

The oral tablet of the present invention has an oval shape, weighs about 820 milligrams (mg), has a length of 16-17 millimeters, a width of 10-11 millimeters, an oval annular surface 101, The annular surface 101 includes two convex surfaces 102 connected to opposite ends thereof. The height of the annular surface 101 is preferably 3 to 4 mm, and the height of each convex surface 102 protruding from the annular surface 101 is preferably 1 to 1.5 mm.

The osteoporosis-improving effect of the oral tablet of the present invention was evaluated by simulating postmenopausal osteoporosis in animals using ovariectomy (OVX) rats.

In that experiment, 10-week-old female rats were randomly divided into six groups, one sham-operated group (Sham) and five ovariectomy (Ovariectomy; OVX) groups. The five ovariectomy groups were further divided into OVX×CMC group, OVX×medicine administration group, OVX×oral tablet administration group 1, 2 and 3. Two weeks after the completion of surgery, the administration of the test substance was started, carboxymethyl cellulose (CMC) was administered to the sham operation group (Sham) and the OVX×CMC group, and the osteoporosis drug alendrone was administered to the OVX×CMC group. (alendronate 2.5 mg/kg), OVX x oral tablet administration group 1 oral tablet dose (339 mg/kg) of the present invention, OVX oral tablet administration 2 group oral tablet double dose of the present invention Dose (678 mg/kg), OVX x Oral Tablet Administration Three groups were given four doses (1356 mg/kg) of the oral tablet of the present invention for 14 consecutive weeks.

After the experimental period, rats underwent serum biochemistry, bone histology and biomechanical analyses.

Serum biochemistry test results: The index of collagen loss rate (NTX) and the index of bone turnover rate (OCN) in OVX x oral tablet administration groups 1, 2, and 3 were all improved compared to the OVX x CMC group. I found out that I do.

Bone tissue analysis results: Bone tissue analysis was performed on the right femur of rats with a microcomputed tomography device, and compared to OVX x CMC, the bone mineral content of OVX oral tablet administration groups 1, 2, and 3 was higher. , Bone mass and trabecular width were clearly increased, while trabecular bone porosity was obviously decreased.

Analysis results by biomechanics: Bone stress change was measured by a three-point bending test method, and the maximum bending strength, hardness, impact absorption capacity and Young's modulus was clearly higher than in the OVX×CMC group.

From the above experimental results, it was found that the oral tablet of the present invention has the effect of preventing osteoporosis or delaying the progression of osteoporosis in ovariectomized rats.

In short, the oral tablet of the present invention contains various nutrients useful for osteoporosis prevention, is excellent in portability and ingestion, and is preservable because the outer surface of the tablet body 10 is coated with the film coating layer 20. It can be taken easily while improving.

10 Tablet body 101 Annular surface 102 Convex surface 11 Hydrolyzed granules derived from chicken breast cartilage 12 Calcium citrate granules 13 Mangosteen extract granules 14 Turmeric extract granules 15 Soybean extract granules 16 Salmon Nasal cartilage-derived extract granules 20 film coating layer

Claims (5)

an oral tablet,
A solid form tablet body composed by mixing a powdery or granular composite formulation, and a film coating layer covering the outer surface of the tablet body,
The composite preparation contains hydrolyzed granules derived from chicken breast cartilage, calcium citrate granules, mangosteen extract granules, turmeric extract granules, and soybean extract granules, An oral tablet comprising a granule of an extract derived from salmon nasal cartilage. The particle size of the hydrolyzed granules derived from chicken breast cartilage is 180 μm or less,
The mangosteen extract granules have a particle size of 380 μm or less,
2. The oral tablet according to claim 1, wherein the turmeric extract powder has a particle size of 180 [mu]m or less. The oral tablet according to claim 1, characterized in that the color of said film coating layer is yellow. 4. The oral tablet according to any one of claims 1 to 3, wherein the oral tablet has an elliptical shape and comprises an elliptical annular surface and two convex surfaces connected to opposite ends of the annular surface. oral tablets. Oral tablet according to claim 4, characterized in that the oral tablet has a length of 16-17 millimeters and a width of 10-11 millimeters.

Images